FPR2 and endolymphatic hydrops: As LXA4 action is mediated by LXA4 receptor (ALX), a formyl-peptide receptor-like 1 (FPRL1) present on cellular membrane [33], the discovery of agents with the potential of increasing Lipoxin A4 (LXA4), and consequently of reducing inflammatory-mediated endolymphatic hydrops, can be relevant to therapeutics of this disease.